G4S plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION
FOR IMMEDIATE RELEASE
8 January 2021
G4S plc
(the “Company”)
Block listing of shares
The Board of the Company (LSE: GFS) (LEI: 549300L3KWKK8X35QR12) announces that it has made a block listing application to the Financial Conduct Authority and the London Stock Exchange PLC for a total of 18,056,000 ordinary shares of 25p each in the capital of the Company to be admitted to the Official List. It is expected that admission will be granted on 11 January 2021.
The shares, when issued, will be issued fully paid and rank pari passu in all respects with the existing issued ordinary shares of the Company. The shares will be issued pursuant to the future vesting of shares under the G4S Long Term Incentive Plan 2014.
- ENDS -
Enquiries
G4S plc
Celine Barroche
Company Secretary
Telephone number: 07841 311 819
Rule 26.1 Disclosure
In accordance with Rule 26.1 of the City Code on Takeovers and Mergers, a copy of this announcement will be available at www.g4s.com/investors/offers, by no later than 12 noon (London time) on the business day following this announcement. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG19.10.2025 16:30:00 CEST | Press release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom